Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing https://t.co/juFr36ayHN https://t.co/W7hD7G8ABX

People may have pre-existing antibodies to SARSCOV2 due to infections with related common cold coronaviruses, homology in the primary amino acid sequences of proteins encoded by these viruses, and molecular mimicry in the important antigenic targets #ncpol

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing https://t.co/juFr36ayHN https://t.co/TphEXaSU6U